Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Cancer remains a leading global cause of mortality, necessitating advanced treatment strategies.
• Adoptive transfer of tumor-infiltrating lymphocytes (TILs) is a promising immunotherapy for malignancies.
• Current TIL therapy efficacy is limited to a subset of cancer patients, highlighting a need for improvement.

Purpose of the Study:

• To systematically review the developmental history of TIL-based therapy.
• To provide a unique perspective on enhancing the multi-dimensional anti-tumor capabilities of TILs.
• To contribute to improving the efficacy and expediting the development of TIL-based therapy.

Main Methods:

• Systematic review and analysis of the developmental history of TIL-based therapy.
• Exploration of novel strategies to augment TIL anti-tumor functions.
• Discussion of insights for enhancing multi-dimensional anti-tumor capabilities.

Main Results:

• Established clinical safety and efficacy of TIL-based therapy through numerous trials.
• Identified limitations in TIL infusion efficacy for inducing anti-tumor responses in a patient subset.
• Presented a novel perspective for enhancing TIL multi-dimensional anti-tumor capabilities.

Conclusions:

• TIL-based therapy is a clinically validated immunotherapy for cancer.
• Enhancing TIL therapy is crucial to broaden its clinical applicability and effectiveness.
• Further research into novel strategies can significantly improve TIL therapy outcomes.